{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:10:13Z","timestamp":1791544213928,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T00:00:00Z","timestamp":1270684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T00:00:00Z","timestamp":1270684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1038\/leu.2010.62","type":"journal-article","created":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T09:44:50Z","timestamp":1270719890000},"page":"1043-1049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease"],"prefix":"10.1038","volume":"24","author":[{"given":"E","family":"Terpos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R J","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,8]]},"reference":[{"key":"BFleu201062_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE . Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165\u2013176.","journal-title":"Cancer Treat Rev"},{"key":"BFleu201062_CR2","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412\u20133420.","journal-title":"J Clin Oncol"},{"key":"BFleu201062_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842\u2013854.","journal-title":"Cancer"},{"key":"BFleu201062_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.2008.000638","volume":"94","author":"E Terpos","year":"2009","unstructured":"Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 2009; 94: 372\u2013379.","journal-title":"Haematologica"},{"key":"BFleu201062_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1046\/j.1365-2141.2003.04050.x","volume":"120","author":"N Abildgaard","year":"2003","unstructured":"Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L . Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003; 120: 235\u2013242.","journal-title":"Br J Haematol"},{"key":"BFleu201062_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3816\/CLM.2007.n.011","volume":"7","author":"A Lipton","year":"2007","unstructured":"Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E et al. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma 2007; 7: 346\u2013353.","journal-title":"Clin Lymphoma Myeloma"},{"key":"BFleu201062_CR7","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102: 1064\u20131069.","journal-title":"Blood"},{"key":"BFleu201062_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59\u201369.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201062_CR9","first-page":"364","volume":"3","author":"F Saad","year":"2005","unstructured":"Saad F, Chen Y, Hei Y . Fractures negatively impact survival in patients with multiple myeloma or bone metastases from solid tumors. Eur J Cancer Suppl 2005; 3: 364 (abstract 1265).","journal-title":"Eur J Cancer Suppl"},{"key":"BFleu201062_CR10","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R . Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007; 110: 1860\u20131867.","journal-title":"Cancer"},{"key":"BFleu201062_CR11","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","volume":"25","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25: 2464\u20132472.","journal-title":"J Clin Oncol"},{"key":"BFleu201062_CR12","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","volume":"23","author":"RE Coleman","year":"2005","unstructured":"Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925\u20134935.","journal-title":"J Clin Oncol"},{"key":"BFleu201062_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","volume":"3","author":"V Hirsh","year":"2008","unstructured":"Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008; 3: 228\u2013236.","journal-title":"J Thorac Oncol"},{"key":"BFleu201062_CR14","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377\u2013387.","journal-title":"Cancer J"},{"key":"BFleu201062_CR15","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613\u20132621.","journal-title":"Cancer"},{"key":"BFleu201062_CR16","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735\u20131744.","journal-title":"Cancer"},{"key":"BFleu201062_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/cncr.23529","volume":"113","author":"A Lipton","year":"2008","unstructured":"Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113: 193\u2013201.","journal-title":"Cancer"},{"key":"BFleu201062_CR18","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","volume":"12","author":"A Lipton","year":"2007","unstructured":"Lipton A, Cook RJ, Major P, Smith MR, Coleman RE . Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007; 12: 1035\u20131043.","journal-title":"Oncologist"},{"key":"BFleu201062_CR19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679\u2013691.","journal-title":"N Engl J Med"},{"key":"BFleu201062_CR20","first-page":"567","volume":"89","author":"N Abildgaard","year":"2004","unstructured":"Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L . Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004; 89: 567\u2013577.","journal-title":"Haematologica"},{"key":"BFleu201062_CR21","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/leu.2008.159","volume":"22","author":"C Jakob","year":"2008","unstructured":"Jakob C, Sterz J, Liebisch P, Mieth M, Rademacher J, Goerke A et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the international staging system in newly diagnosed symptomatic multiple myeloma. Leukemia 2008; 22: 1767\u20131772.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"BFleu201062_CR22","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S1557-9190(11)70454-1","volume":"9","author":"JR Berenson","year":"2009","unstructured":"Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH et al. Overall survival among patients with multiple myeloma (MM) treated with zoledronic acid (ZOL). Clin Lymphoma Myeloma 2009; 9 (Suppl 1): S12\u2013S13 (abstract A088).","journal-title":"Clin Lymphoma Myeloma"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201062","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:43:54Z","timestamp":1648734234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,8]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["BFleu201062"],"URL":"https:\/\/doi.org\/10.1038\/leu.2010.62","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,8]]},"assertion":[{"value":"5 November 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Evangelos Terpos has received honoraria and research funding from Novartis and Janssen-Cilag. James Berenson has received honoraria and consulting fees from Novartis and has earlier given expert testimony on their behalf. Richard Cook has received honoraria and consulting fees from Abbott, Amgen, GlaxoSmithKline, and Novartis. Allan Lipton has participated as a consultant for Amgen, Novartis, Merck, Monogram, and GlaxoSmithKline; received honoraria from Amgen, Pfizer, and Novartis; and received research funding from Novartis, Monogram Biosciences, and Oncogene Sciences. Robert Coleman has received honoraria and consulting fees from Novartis and has earlier given expert testimony on their behalf.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}